Aromatase inhibitors have shown to be more effective than tamoxifen in various scenarios in breast cancer, generally with a lower toxicity profile (Eiermann et al, 2001; Crivellari et al, 2008; Cuzick et al, 2010). Here, CYP19A1 is linked to breast carcinoma.